Abstract In contrast to other neurodegenerative diseases, sporadic Creutzfeldt-Jakob disease (sCJD) is rarely diagnosed in patients older than 75 years. Data describing the characteristics of sCJD in the very old are rare and inconclusive. Therefore, a historical cohort study was designed to evaluate clinical, cerebrospinal fluid (CSF), electroencephalography (EEG), and magnetic resonance imaging (MRI) features of this group. Patients older than 75 years identified via the German surveillance program from 2001 to 2012 (n = 73) were compared to a random subsample of sCJD patients younger than 75 (n = 73) from the same time period using an historical cohort design. Older patients showed a faster disease progression represented by an earlier point of diagnosis and a shorter survival time (p \ 0.001). In the early stages of disease, older patients presented slightly more often with dementia (p = 0.127) or dysarthria (p = 0.238), whereas disorders of the extrapyramidal (p = 0.056) and visual system (p = 0.015) were more common in the younger group. Atypical MRI profiles such as MRI lesions restricted to one hemisphere (p \ 0.001) or cortical lesions only (p = 0.258) were found more frequently in patients older than 75 years, whereas typical cortical and basal ganglia hyperintensities were more common in the younger group (p = 0.001). We demonstrated for the first time that patients with late-onset sCJD differ from younger sCJD patients with respect to MRI profiles and initial clinical presentation, but not among CSF markers. Misclassification of Creutzfeldt-Jakob disease cases in patients older than 75 years seems likely due to atypical clinical and radiological presentation. This might contribute to lower sCJD incidence rates in this age group.
Introduction
Creutzfeldt-Jakob disease (CJD) is a rare fatal prion disease typically associated with rapid-progressive dementia, ataxia, visual symptoms, and myoclonus. According to the underlying cause of disease, it can further be divided into genetic, iatrogenic, and sporadic Creutzfeldt-Jakob disease (sCJD) [1, 2] . Whereas a definite diagnosis is restricted to neuropathological examination, in vivo diagnosis of sCJD is based on clinical symptoms, cerebrospinal fluid (CSF) markers, magnetic resonance imaging (MRI) and electroencephalography (EEG) profiles [3, 4] . Six molecular subtypes (MM-1, MM-2, MV-1, MV-2, VV-1, VV-2) of sCJD have been identified [5] . Classification is based on the methionine-valine polymorphism at codon 129 of the prion protein gene (PRNP) and on two distinct types of prion protein (PrP Sc type 1 and 2). The subtypes differ from each other with respect to disease course, survival time, and CSF and MRI profiles [2, 5] .
Although sCJD is transmissible from one patient to another by transfer of neuronal tissue and thereby demonstrates infectious features, it is primarily seen as a neurodegenerative disease [6] . Age-specific incidence rates increase with age in most neurodegenerative diseases (e.g. Alzheimer's disease, Parkinson's disease) [7] ; however, sCJD incidence rates are highest between 60 and 75 years of age and drop down thereafter [8] [9] [10] . The drop can be located at a cut off of 75 years in a US-based study by Holman et al., whereas it seemed to be slightly higher in two European studies. However, age is grouped in bands of 10 years in these studies and a re-analysis of the data from the study of Heinemann et al. could confirm a cutoff of 75 years in this study population as well.
Reasons for lower incidence rates in patients older than 75 years have been proposed in recent years. While some researchers argued that this finding might support the hypothesis of the transmission of an infectious agent within a specific age frame and with a specific incubation period, others attributed the lower rates in the oldest age groups to surveillance problems based on atypical clinical presentation and misclassification as other types of dementia [8, 11] . The latter hypothesis is supported by the observation that age-specific sCJD incidence rates have been increasing in these age groups in those countries that started an active CJD surveillance program [9, 12, 13] .
Despite this unsolved epidemiological peculiarity of sCJD, there are no data available describing the characteristics of CJD in the very elderly.
It was, therefore, the aim of this study to investigate characteristics of patients with late-onset sCJD and to evaluate how these characteristics might contribute to decreasing incidence rates in individuals over 75 years of age.
Methods

Study design and study population
We employed a historical cohort study design, using data from an ongoing surveillance study of the German National Reference Center for Transmissible Spongiform Encephalopathies (NRZ-TSE). In Germany, all patients suspected to suffer from CJD are referred to the NRZ-TSE for expert opinion. These patients are then followed until an alternative diagnosis can be established or until death. Patients are visited by a study physician at the point of diagnosis; regular phone calls with relatives and family doctors are performed thereafter.
Patients were considered for inclusion in this study if they were diagnosed with probable or definite CJD between 2001 and 2012. All patients with familiar or iatrogenic CJD were excluded. In this time period 1,442 sCJD patients were identified via the German surveillance system. For inclusion in this study, patients must have been examined by a study physician of the NRZ-TSE according to standardized protocols. In addition, MRI scans of the patients must have been available to the study investigators.
An age older than 75 years at disease onset was defined as the exposure of interest. A total of 297 patients with definite or probable sCJD were identified in this age range representing 20.6 % of all patients with a probable or definite diagnosis between 2001 and 2012. After applying the inclusion criteria as stated above, 73 individuals older than 75 years ([75 years) were identified and included in this study. Of the 224 patients excluded from the study, 121 (40.7 %) were not visited by a study physician, 28 (9.4 %) did not provide an MRI scan to the study investigators and 75 (25.3 %) of the 224 were neither visited nor did they provide an MRI scan. There were no significant differences between included and excluded patients in age, sex, duration of disease, autopsy rates, and proportion of available subtypes.
Seventy-three patients were selected as the non-exposed comparison group from all sCJD patients younger than 75 years (\75 years) at disease onset (diagnosed with sCJD between 2001 and 2012, and eligible for this study with respect to the above-named inclusion and exclusion criteria) by using a random selection process. The selected patients were shown to be representative for the source population with respect to age, sex, duration of disease, autopsy rates, and proportion of available subtypes.
For use as a cohort study, the first day of follow-up was defined as the date of first symptom presentation; all patients were followed up until death.
Diagnostic tests
Clinical presentation
All patients enrolled in this study were examined by a study physician according to a standardized protocol, including neurological examination and neuropsychological testing. Patient histories were taken from each patient using (a) semistructured interviews with close relatives, (b) interviews with attending physicians and primary physicians, and (c) hospital records. Duration of disease (from date of first symptom until death) was split into three parts of equal length, for each individual patient in order to provide a time frame that allowed us to account for differences in disease progression (first, second, and third part of disease).
CSF analyses
Protein 14-3-3 was analyzed in all study participants by Western blot according to previously published protocols [14, 15] . Western blot results were classified in a binary way (negative = no band present, positive = band present). A positive and a negative control were added to each blot for quality control. CSF Tau protein was quantitatively analyzed using a commercially available enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (Innogenetics, Ghent, Belgium). A Tau test was considered positive at a cut off level of[1,300 pg/ ml [16] .
EEG analyses
Electroencephalograms (EEGs) were reviewed by a study physician (LR) according to World Health Organization (WHO) criteria for EEG profiles in CJD patients [3] . EEG profiles were reviewed by a second study physician (AK) in a random subsample of study participants to check for inter-reader reliability. Both investigators were blinded to the exposure status of the respective patient.
MRI analyses
Magnetic resonance imaging (MRI) profiles of all study participants were assessed by a study physician (LR) according to a standardized protocol. The protocol used in this study included pathological findings in three different MRI weightings (DWI, FLAIR, T2) as well as brain atrophy and white matter lesions. Findings were classified as abnormal if present in at least one weighting. The term ''hyperintensities'' was used for describing typical sCJD findings (high-signal abnormalities in DWI/FLAIR). MRI profiles were reviewed by a second study physician (DS) in a random subset of study participants to check for interreader reliability. Both investigators were blinded to the exposure status of the respective patient. In case of differing judgments for EEG or MRI, cases were discussed between reviewers and a consensus opinion was formed.
Statistical analyses
Data analyses were performed using SPSS 19.0 (SPSS Inc., Chicago, USA). Categorical outcome variables were assessed using cross tabulation, odds ratios (OR), and chisquared or Fisher's tests as appropriate. Continuous variables were described using means [with standard deviation (SD)] and medians [with interquartile range (IQR)], and were analyzed using t tests and Wilcoxon rank-sum tests as appropriate. Due to differences in time from first symptom to diagnosis, multivariable analyses were performed using logistic regression models and multiple linear regression models as appropriate. Survival analyses for time from first symptom to diagnosis and for time from first symptom to death were performed with Kaplan-Meier estimates and Cox regression models. For all multivariable analyses, exposure variables and potential confounders were initially tested individually for their effect on the outcome of interest. Potential confounders were then introduced in the model in the order of their univariable effect. A forward selection process was chosen to assess the influence of potential confounders on the effect of the exposure of interest. Variables were defined as confounders and kept in the model if they were associated with the exposure of interest, as well as with the outcome, and if the effect size of the exposure was changed by at least 10 %.
Sensitivity analyses
Several sensitivity analyses were performed in this study. At first, the main analyses of this study were repeated, restricting the study population to definite sCJD cases only. A second sensitivity analysis was then performed with a cut off of 80 years in order to allow for potential uncertainties in previous incidence studies.
Ethics approval
This study was conducted according to the revised Declaration of Helsinki and Good Clinical Practice guidelines. Informed consent was given by all study participants or their legal next of kin. Ethics approval was obtained from the Ethics Committee of the University of Göttingen (Study 11/11/93).
Results
Seventy-three patients older than 75 years and 73 patients younger than 75 years with probable or definite sCJD were included in this historical cohort study. Individuals older than 75 years were slightly more likely to be female (63.0 vs. 50.7 %, p = 0.133), but were less likely to get autopsied (45.2 vs. 58.9 %, p = 0.098) or to be investigated for molecular subtype (13.7 vs. 49.3 %, p \ 0.001) than patients younger than 75 years ( Table 1 ). The proportion of missing values for molecular subtype was high in both groups (86.3 vs. 50.7 %), so that the observed pattern of molecular subtypes cannot be generalized to the respective groups. However, MM-1 subtypes were more frequent in the older patient group, whereas atypical subtypes such as MM-2 and VV-1 were only found in the younger age group (Table 1) . Older individuals had a faster course of disease represented by a shorter time from first symptom to diagnosis and by a shorter survival time when compared to the younger patient group [hazard ratio (95 % confidence interval): 2.36 (1.65-3.38) and 2.08 (1.48-2.94), Fig. 1] . When restricting the analysis to the initial clinical presentation (representing the first third of disease duration), the older study group showed slightly more often symptoms of dementia (p = 0.127) and dysarthria (p = 0.238), whereas visual disorders (p = 0.015), extrapyramidal signs (p = 0.056), vertigo (p = 0.043) and myoclonus (p = 0.028) were considerably more frequent in the younger group (Table 2) .
When expanding this analysis to the entire duration of disease, patients under 75 years were more likely to develop vertigo (p = 0.007) and visual symptoms (p = 0.010), whereas patients over 75 years had a higher risk of the presence of pyramidal signs (p = 0.098, Table 2 ).
No differences could be shown in CSF biomarker profiles or EEG profiles between groups. This did not change after adjusting for time from first symptom to the date of the respective CSF or EEG investigation (Table 3) .
MRI profiles of patients older than 75 years were significantly less frequently compatible with established MRI criteria for sCJD than MRI profiles of the younger group [odds ratio (OR), 95 % CI: 0.14 (0.04-0.43)]. Typical DWI and FLAIR hyperintensities of the cortex and the basal ganglia could be seen in 36.1 and 58.3 %, respectively, of the older patients, but in 61.6 and 83.6 % of the younger patients (Table 4 , p \ 0.001). Atypical presentations with pathological hyperintensities restricted to one hemisphere (12.3 vs 0.0 %) or restricted to cortical regions only (15.1 vs. 9.6 %) were found more often in patients older than 75 years. As expected, white matter lesions were found more often in the older group (67.6 vs. 39.7 %, p \ 0.001), whereas there was no difference in the frequency of brain atrophy between groups (19.2 vs. 26.0 %, p = 0.322, Table 4 ). Results could be confirmed in a multivariable analysis adjusted for sex, and time from first symptom to MRI.
Sensitivity analyses restricted to definite sCJD cases only (n = 33 in the older group vs. n = 43 in the younger group) or to patients above the age of 80 (n = 23) showed results consistent with the primary analyses of this study.
Discussion
The aim of this study was to compare characteristics of late-onset sCJD patients with those of younger sCJD patients in order to derive hypotheses for the reasons of low sCJD incidence rates in individuals older than 75 years. In this study we have demonstrated for the first time that sCJD patients older than 75 years differ from younger sCJD patients with respect to MRI profiles and initial clinical presentation, but not with respect to CSF markers or EEG profiles.
Symptoms typically associated with sCJD could be observed more frequently in the younger age group, in both early and late disease (Table 2) . However, dementia, dysarthria, and pyramidal signs were seen more often in lateonset sCJD cases. Although all patients were systematically examined by trained physicians, the first examination typically took place after the first third of disease duration such that differences in this time interval could be attributable to information bias, e.g., since younger patients are reviewed more thoroughly by primary care physicians. However, this can be excluded for differences observed thereafter.
We found no differences in CSF markers, both when adjusted for the timing of lumbar puncture and when not. MRI profiles were available for all participants. Presentations compatible with established diagnostic criteria for sCJD were less frequently observed in older individuals. Interestingly, late-onset sCJD patients not only showed typical MRI profiles less frequently, but also more frequently exhibited atypical patterns like DWI and FLAIR hyperintensities restricted to one hemisphere or to cortical regions only.
One might assume that observed differences between older and younger sCJD patients are due to the faster course of disease in late-onset sCJD patients resulting in an earlier diagnosis, and thereby also in a less typical clinical presentation and MRI pattern. However, multivariable Table 2 Clinical signs and symptoms during the first third of disease duration and during the total duration of disease (by age at disease onset) Symptoms Present within first third of disease Present at any point of disease
Group older than 75 years (n = 73)
Group younger than 75 years (n = 73) p value* Group older than 75 years (n = 73)
Group younger than 75 years (n = 73) analyses adjusted for differences in time to diagnosis confirmed the primary results of this study and showed that observed differences between both groups were independent of different disease progression rates. This study included the largest sample of late-onset sCJD cases investigated so far. However, the present study was restricted to sCJD cases that were suspected to be a case pre-mortem and that were diagnosed in collaboration with the German National Reference cCentre. Therefore, it must be kept in mind that features identified in this study do not necessarily apply to late-onset CJD patients who have not been identified correctly within the German surveillance system. However, in a sensitivity analysis restricted to definite sCJD cases only, the major results of this study could be confirmed.
Since only patients with available MRI scans were included in this study, the study might have been prone to selection bias by over-representing those patients in need of extensive diagnostic procedures, and thus, those with an atypical course of disease. However, this would not have affected the older patients only, since the same inclusion criteria were applied for both older and younger patients. The exclusion of patients without an available MRI might have reduced the generalizability of our study, but has not affected the validity of the study results. In addition, we could confirm that patients older than 75 years included in this study were representative for all patients older than 75 in our database with respect to age, sex, duration of disease, autopsy rates, and the proportion of available subtypes.
A major limitation of our study is the low proportion of patients with identified subtypes within the study population. It is possible that observed differences between groups are at least partly due to differences in subtypes. When looking only at patients with identified subtypes, late-onset sCJD cases harbored more often MM-1 subtypes than younger CJD patients; there were no atypical subtypes in this patient group. This is consistent with existing evidence showing that isolated cortical hyperintensities are more common in patients with PrP Sc Type 1 [17] . However, the observed differences in subtypes in our study must be evaluated in the light of the extremely high proportion of missing values. While there is no evidence that systematic differences in subtypes are responsible for the observed clinical and MRI differences, it cannot be ruled out due to the high proportion of missing subtypes. This limitation does not affect the clinical relevance of the study, as the observed differences are important for the assessment of the clinical diagnosis independently of subtype distributions in the respective age groups. However, it will be interesting for future prospective studies to confirm the results of this study within a study population with high proportions of definite subtypes. As a result of this study it can be concluded that patients older than 75 years detected by current diagnostic guidelines seem to more commonly display atypical features with respect to clinical and MRI characteristics. Some of these characteristics may be attributable to molecular subtypes that differ between the two groups. It must be kept in mind that the conclusions drawn from this study are limited by the fact that the study is restricted to sCJD cases that have been diagnosed given our current ability to detect sCJD, and might not be transferable to the cases we do not detect.
However, due to (1) the rapid course of disease, (2) a less impressive initial clinical presentation (frequently, as dementia), and (3) atypical MRI profiles, it seems likely that a considerable proportion of late-onset sCJD cases are not identified correctly and are misdiagnosed as other forms of dementia. Awareness of this variation in clinical presentation and MRI findings in older patients could improve the detection of sCJD in elderly patients who are beyond the average age range for diagnosis. This might be helpful for both correct diagnostic classification in future studies and the application of potential treatments.
